1. Scrip
  2. >>Business
  3. >>Deals

Sobi Exits Nirsevimab Cost-Sharing Pact With AstraZeneca, Simplifies Royalty Deal With Sanofi

 
• By Joseph Haas

Deal Snapshot: Approved in the EU/UK and nearing a US approval, rights to the RSV prophylaxis for infants and newborns are simplified in the pair of agreements unveiled by Synagis owner Sobi.

Businessman sinking in heap of documents and asking for help
Sobi says new agreements simplify rights pertaining to nirsevimab

Who: Swedish Orphan Biovitrum AB/Sanofi/AstraZeneca

What: Sobi simplified its revenue streams tied to the respiratory syncytial virus candidate nirsevimab by inking a new US royalty...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business